Replies to post #102849 on Biotech Values

[DewDiligence]

…is it safe to say then that SNY does have a floor that it cannot fall through for enoxaparin pricing lest they run the risk of another PR for reduced guidance or missing their previous guidance?

Please see my reply to zipjet in #msg-53835981.